The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer.
Saved in:
| Title: | The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer. |
|---|---|
| Authors: | Liu Y; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China., Yuan L; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China., Lin Z; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China., Huixian M; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China., Huangyang M; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China., Cheng W; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. wenjunchengdoc@163.com. |
| Source: | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2025 Jan; Vol. 27 (1), pp. 340-350. Date of Electronic Publication: 2024 Jun 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38904923 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Yuan+L%22">Yuan L</searchLink>; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Lin+Z%22">Lin Z</searchLink>; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Huixian+M%22">Huixian M</searchLink>; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Huangyang+M%22">Huangyang M</searchLink>; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.<br /><searchLink fieldCode="AU" term="%22Cheng+W%22">Cheng W</searchLink>; Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. wenjunchengdoc@163.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101247119%22">Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</searchLink> [Clin Transl Oncol] 2025 Jan; Vol. 27 (1), pp. 340-350. <i>Date of Electronic Publication: </i>2024 Jun 21. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Italia%22">Springer Italia </searchLink><i>Country of Publication: </i>Italy <i>NLM ID: </i>101247119 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1699-3055 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221699048X%22">1699048X </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38904923 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12094-024-03569-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 340 Titles: – TitleFull: The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Liu Y – PersonEntity: Name: NameFull: Yuan L – PersonEntity: Name: NameFull: Lin Z – PersonEntity: Name: NameFull: Huixian M – PersonEntity: Name: NameFull: Huangyang M – PersonEntity: Name: NameFull: Cheng W IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2025 Jan Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1699-3055 Numbering: – Type: volume Value: 27 – Type: issue Value: 1 Titles: – TitleFull: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico Type: main |
| ResultId | 1 |
